AR124917A1 - Moléculas de unión a vegfa - Google Patents
Moléculas de unión a vegfaInfo
- Publication number
- AR124917A1 AR124917A1 ARP220100348A ARP220100348A AR124917A1 AR 124917 A1 AR124917 A1 AR 124917A1 AR P220100348 A ARP220100348 A AR P220100348A AR P220100348 A ARP220100348 A AR P220100348A AR 124917 A1 AR124917 A1 AR 124917A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding molecule
- vegfa
- car
- nucleic acid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 11
- 102000036639 antigens Human genes 0.000 abstract 11
- 108091007433 antigens Proteins 0.000 abstract 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 abstract 6
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000013604 expression vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Una molécula de unión a antígeno, opcionalmente aislada, que se une a VEGFA, en donde la molécula de unión a antígeno comprende una secuencia de anticuerpo de dominio único que incorpora las siguientes CDR: CDR1 que tiene la secuencia de aminoácidos de la SEQ ID Nº 13, CDR2 que tiene la secuencia de aminoácidos de la SEQ ID Nº 14, CDR3 que tiene la secuencia de aminoácidos de la SEQ ID Nº 15. Reivindicación 10: Un receptor de antígeno quimérico (CAR) que comprende una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9. Reivindicación 11: Un ácido nucleico, opcionalmente aislado, que codifica una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, o un CAR de acuerdo con la reivindicación 10. Reivindicación 12: Un vector de expresión que comprende un ácido nucleico de acuerdo con la reivindicación 11. Reivindicación 13: Una célula que comprende una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, un CAR de acuerdo con la reivindicación 10, un ácido nucleico de acuerdo con la reivindicación 11, o un vector de expresión de acuerdo con la reivindicación 12. Reivindicación 14: Un método para producir una molécula de unión a antígeno que se une a VEGFA, que comprende cultivar una célula de acuerdo con la reivindicación 13 bajo condiciones adecuadas para expresión por la célula de una molécula de unión a antígeno o CAR. Reivindicación 15: Una composición que comprende una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, un CAR de acuerdo con la reivindicación 10, un ácido nucleico de acuerdo con la reivindicación 11, un vector de expresión de acuerdo con la reivindicación 12, o una célula de acuerdo con la reivindicación 13, y un portador, diluyente, excipiente o adyuvante farmacéuticamente aceptable. Reivindicación 21: Un complejo in vitro, opcionalmente aislado, que comprende una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9 unida a VEGFA. Reivindicación 22: Un método para detectar VEGFA en una muestra, que comprende poner en contacto una muestra que contiene o que se sospecha que contiene, VEGFA con una molécula de unión a antígeno de acuerdo con una cualquiera de las reivindicaciones 1 a 9, y detectar la formación de un complejo de la molécula de unión a antígeno con VEGFA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202101681W | 2021-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124917A1 true AR124917A1 (es) | 2023-05-17 |
Family
ID=80685523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100348A AR124917A1 (es) | 2021-02-19 | 2022-02-18 | Moléculas de unión a vegfa |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240228602A9 (es) |
| EP (2) | EP4294838A1 (es) |
| JP (2) | JP2024512260A (es) |
| KR (2) | KR20230165901A (es) |
| CN (2) | CN117279941A (es) |
| AR (1) | AR124917A1 (es) |
| AU (2) | AU2022223337A1 (es) |
| CA (2) | CA3208368A1 (es) |
| WO (2) | WO2022175474A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025534252A (ja) * | 2022-09-14 | 2025-10-15 | 尋済生物科技（北京）有限公司 | 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用 |
| CN119039450A (zh) * | 2023-05-22 | 2024-11-29 | 上海君实生物医药科技股份有限公司 | 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008259513B2 (en) * | 2007-06-06 | 2014-07-24 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| KR100883430B1 (ko) * | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US9499612B2 (en) * | 2011-07-27 | 2016-11-22 | Glaxo Group Limited | Antigen binding constructs |
| US11053302B2 (en) | 2014-11-05 | 2021-07-06 | Nanyang Technological University | Stabilized and autonomous antibody VH domain |
-
2022
- 2022-02-18 CN CN202280029374.9A patent/CN117279941A/zh active Pending
- 2022-02-18 AU AU2022223337A patent/AU2022223337A1/en active Pending
- 2022-02-18 AR ARP220100348A patent/AR124917A1/es unknown
- 2022-02-18 CN CN202280015698.7A patent/CN117242092A/zh active Pending
- 2022-02-18 WO PCT/EP2022/054123 patent/WO2022175474A1/en not_active Ceased
- 2022-02-18 JP JP2023550552A patent/JP2024512260A/ja active Pending
- 2022-02-18 US US18/277,749 patent/US20240228602A9/en active Pending
- 2022-02-18 CA CA3208368A patent/CA3208368A1/en active Pending
- 2022-02-18 US US18/277,738 patent/US20240228601A9/en active Pending
- 2022-02-18 AU AU2022222311A patent/AU2022222311A1/en active Pending
- 2022-02-18 CA CA3208389A patent/CA3208389A1/en active Pending
- 2022-02-18 JP JP2023550275A patent/JP2024513644A/ja active Pending
- 2022-02-18 KR KR1020237031774A patent/KR20230165901A/ko active Pending
- 2022-02-18 EP EP22708095.9A patent/EP4294838A1/en active Pending
- 2022-02-18 WO PCT/EP2022/054137 patent/WO2022175481A1/en not_active Ceased
- 2022-02-18 KR KR1020237031776A patent/KR20230165902A/ko active Pending
- 2022-02-18 EP EP22709293.9A patent/EP4294839A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022175474A1 (en) | 2022-08-25 |
| AU2022222311A1 (en) | 2023-09-21 |
| CN117242092A (zh) | 2023-12-15 |
| US20240228601A9 (en) | 2024-07-11 |
| JP2024513644A (ja) | 2024-03-27 |
| EP4294839A1 (en) | 2023-12-27 |
| JP2024512260A (ja) | 2024-03-19 |
| US20240132579A1 (en) | 2024-04-25 |
| EP4294838A1 (en) | 2023-12-27 |
| KR20230165901A (ko) | 2023-12-05 |
| WO2022175481A1 (en) | 2022-08-25 |
| CA3208389A1 (en) | 2022-08-25 |
| CA3208368A1 (en) | 2022-08-25 |
| KR20230165902A (ko) | 2023-12-05 |
| AU2022223337A1 (en) | 2023-09-21 |
| US20240228602A9 (en) | 2024-07-11 |
| US20240132580A1 (en) | 2024-04-25 |
| CN117279941A (zh) | 2023-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112574307B (zh) | 抗人Claudin18.2抗体及其应用 | |
| JP7406488B2 (ja) | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 | |
| CN105579472B (zh) | 新型抗体框架 | |
| KR102100817B1 (ko) | 이중 항원-유도된 이분 기능 상보성 | |
| JP2023115024A (ja) | 新規の安定した抗体の可変領域フレームワークの組み合わせ | |
| CN110872350A (zh) | 抗cd47抗体及其应用 | |
| JP2020534830A5 (es) | ||
| AR123997A1 (es) | ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2 | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| AR124917A1 (es) | Moléculas de unión a vegfa | |
| US9303086B2 (en) | Anti-hDlk-1 antibody having an antitumor activity in vivo | |
| CN110177571B (zh) | 工程化抗体及其用途 | |
| EP3243838A1 (en) | Humanized monoclonal antibody and uses thereof | |
| AR126759A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| AU2019268959B2 (en) | Use for preventing and treating myeloid-derived suppressor cell-related diseases | |
| WO2024260440A1 (zh) | 一种能够结合lilrb2的抗体或其抗原结合片段 | |
| CN108348780A (zh) | 用作用于环磷酰胺和异环磷酰胺的免疫分析的免疫原和分析缀合物的环磷酰胺类似物 | |
| JP2021512599A (ja) | 中東呼吸器症候群コロナウイルスに対して中和活性を有する結合分子 | |
| CN114174515A (zh) | tau中的构象特异性表位、其抗体和其相关方法 | |
| TWI889766B (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| AR125040A1 (es) | Constructos anti-vista y usos de estos | |
| JP2018502577A5 (es) | ||
| CN107250162A (zh) | 新的人源化adam17抗体 | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR130506A1 (es) | Anticuerpos anti-lair1 humano |